Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Breast Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Breast Neoplasm

Cancer Family

Breast Neoplasm

CI-CAN-00000007Explore in graph →

Non-malignant2,894 active trials43 approved drugs310 evidence items

NCIt: C2910
OncoTree: BNNOS
MeSH: D000069584
MeSH: D001943

Overview
Statistics
Survival
Genomics33
Variants & evidence310
Drugs79
Trials13867
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (268)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 151–175 of 268 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
· JAMA · 2010 · PMID 21177507 · validated civic_curation pubmed
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
· Lancet Oncol · 2011 · PMID 21862407 · validated civic_curation pubmed
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
· J Clin Oncol · 2017 · PMID 27870574 · validated civic_curation pubmed
PIK3CA mutation associates with improved outcome in breast cancer.
· Clin Cancer Res · 2009 · PMID 19671852 · validated civic_curation pubmed
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
· Breast Cancer Res Treat · 2011 · PMID 21594665 · validated civic_curation pubmed
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
· Cancer Res · 2000 · PMID 10786679 · validated civic_curation pubmed
Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
· Oncotarget · 2017 · PMID 28430626

Showing 151–175 of 268 publications

← Previous
1
…
6
7
8
…
11
Next →

· validated civic_curation

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.

· Clin Cancer Res · 2007 · PMID 17575221 · validated civic_curation pubmed

PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.

· Breast Cancer Res · 2008 · PMID 18371219 · validated civic_curation pubmed

KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.

· Oncogene · 2018 · PMID 29755131 · validated civic_curation pubmed

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.

· J Clin Oncol · 2019 · PMID 30807234 · validated civic_curation pubmed

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

· Ann Oncol · 2014 · PMID 25193991 · validated civic_curation pubmed

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.

· Clin Cancer Res · 2016 · PMID 26920887 · validated civic_curation pubmed

A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma.

· Genes Chromosomes Cancer · 2004 · PMID 15101049 · validated civic_curation pubmed

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.

· Cancer Cell · 2002 · PMID 12450792 · validated civic_curation pubmed

Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.

· Mod Pathol · 2017 · PMID 28548128 · validated civic_curation pubmed

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.

· JCO Precis Oncol · 2022 · PMID 35939768 · validated civic_curation pubmed

Kataegis Expression Signature in Breast Cancer Is Associated with Late Onset, Better Prognosis, and Higher HER2 Levels.

· Cell Rep · 2016 · PMID 27373164 · validated civic_curation pubmed

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.

· Cancer Discov · 2018 · PMID 30206110 · validated civic_curation pubmed

Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients.

· Breast Cancer Res Treat · 2020 · PMID 32852708 · validated civic_curation pubmed

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.

· Clin Cancer Res · 2019 · PMID 31371343 · validated civic_curation pubmed

Genomic characterization of tumor mutational burden-high breast carcinomas.

· NPJ Precis Oncol · 2025 · PMID 40775459 · validated civic_curation pubmed

FGFR1 is an adverse outcome indicator for luminal A breast cancers.

· Oncotarget · 2016 · PMID 26673008 · validated civic_curation pubmed

A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.

· Clin Breast Cancer · 2015 · PMID 25537159 · validated civic_curation pubmed

Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

· Mol Cancer Ther · 2004 · PMID 15486187 · validated civic_curation pubmed